Skip to main content

Table 1 Patient characteristics (n = 50)

From: Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib

Characteristics

Data

Age, years, median (range)

58 (34–79)

Race

 White

47 (94%)

 Black

3 (6%)

Menopausal status

 Premenopausal

18 (36%)

 Postmenopausal

32 (64%)

PgR

 Negative

3 (6%)

 Positive

47 (94%)

Tumor grade

 1

12 (24%)

 2

31 (62%)

 3

7 (14%)

Clinical stage

 II

36 (72%)

 III

14 (28%)

  1. PgR - Progesterone